Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
84%
Antivitamin K
42%
Cohort Study
36%
Anticoagulant Agent
33%
Thromboembolism
25%
Dabigatran
22%
Cerebrovascular Accident
20%
Bleeding
20%
Drug Metabolism
16%
Gastric Inhibitory Polypeptide
16%
Concurrent Infection
16%
Infection
16%
Biological Marker
16%
Cathepsin K
16%
Long Untranslated RNA
16%
Anticoagulation Therapy
9%
Adenosine Triphosphate
8%
IC50
8%
Liver Cell Carcinoma
8%
Drug Toxicity
8%
Retinol
7%
All Cause Mortality
6%
Untranslated RNA
5%
Brain Ischemia
5%
Apixaban
5%
Biochemistry, Genetics and Molecular Biology
Osteoclast
100%
Osteolysis
63%
Atrial Fibrillation
33%
Osteoclast Activity
25%
Precursor
19%
Cohort Study
18%
Osteoblast
16%
Single-Nucleotide Polymorphism
16%
Tumor Spheroid
16%
Dynamics
16%
Gastric Inhibitory Polypeptide
16%
Long Non-Coding RNA
16%
Cathepsin K
16%
Anticoagulation
13%
IC50
11%
Ossification
9%
Osteoclastogenesis
8%
Familial Atrial Fibrillation
8%
Dendritic Cell
6%
Membrane Protein
6%
Transmembrane Protein
6%
CD14
6%
Drug Metabolism
5%
Medicine and Dentistry
Atrial Fibrillation
50%
Anticoagulation
35%
Antithrombotic
33%
Osteoclast
33%
Vitamin K Antagonist
27%
Apoplexy
20%
Osteolysis
19%
Hazard Ratio
19%
Trypsinization
16%
Thromboembolism
16%
Bleeding
16%
Cohort Analysis
16%
Infection
16%
Tumor Spheroid
16%
Long Untranslated RNA
16%
Anticoagulant Therapy
13%
Cathepsin K
10%
CHA2DS2-VASc Score
8%
Retinol
7%
Osteoclastogenesis
7%
Drug Metabolism
6%
Biological Marker
6%
Apixaban
5%
Dabigatran
5%
Major Bleeding
5%
All Cause Mortality
5%
IC50
5%
